Southwest X-Ray deploys Gamma Medica’s LumaGEM MBI system for screening women with dense breast tissue

NewsGuard 100/100 Score

Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Southwest X-Ray, the leading outpatient services provider in El Paso, TX, has installed Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in its Gateway Blvd. West location. Southwest X-Ray will utilize the LumaGEM MBI system as a secondary diagnostic tool for inconclusive mammography screenings in patients with dense breast tissue.

“The installation of our LumaGEM MBI system in a standalone diagnostic imaging center is indicative of the market’s recognition of MBI as a standard secondary screening and diagnostic tool to the traditional mammogram,” stated Philip Croxford, CEO of Gamma Medica. “Our partnership with Southwest X-Ray not only offers the organization a breakthrough in the early detection of breast cancer in women who have dense breast tissue, but is a testament to the important shift in the evolving healthcare landscape toward a future of personalized care.”

MBI is a groundbreaking technology that eliminates key shortcomings of traditional anatomical imaging technologies such as mammography and ultrasound by significantly improving early diagnosis of breast cancer in women with dense breast tissue. Dense breast tissue makes it more it challenging to detect cancer, as both lesions and dense tissue appear white on a traditional mammogram. According to recent publications, MBI is a functional imaging modality that highlights metabolic activity in breast tumors not visible on mammography due to tissue density, thereby leading to earlier, specific diagnosis, improved outcomes and lowered costs. LumaGEM has also proven to reduce painful and costly biopsies by 50 percent.

“Our goal is to provide our patients with the best quality of care by utilizing the latest enhancements in hardware and software,” said Roy Jauernek, M.D., a radiologist at Southwest X-Ray. “We needed to install a secondary tool that would provide our patients and staff with accurate results. Given the significant increase in cancer detection rates through the use of the LumaGEM MBI system, we are confident this installation will assist us in early diagnosis of breast cancer, specifically for our patients with dense breast tissue.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery